Dobutamine Effects in Wild-type Transthyretin Amyloid Heart Disease
Tests dobutamine infusion in older adults with wild-type transthyretin amyloid heart disease.
Plain-language title generated from the registry record
Registry title: Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
Key facts
- Where
- Aarhus, DenmarkSee the site
- Phase
- Phase 1/2
Where in Denmark
- Department of Cardiology Aarhus University HospitalAarhus, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Steen Hvitfeldt Poulsen
- Trial code
- NCT06318260
- Record updated
- 1 June 2026
- Original description
The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main questions it aims to answer are:Read full original descriptionShow less
Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main questions it aims to answer are:
* What are the effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt. * Safety of dobutamine infusion in this patient population.
Participants will receive increasing doses of dobutamine infusion, and the effects on cardiac output and filling pressures will be assessed simultaneously by echocardiography and right heart catheterization.
Inclusion: ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and/or endomyocardial biopsy; Treated with loop diuretics; New York Heart Association class II-IV; Age ≥ 65 years; Left ventricular ejection fraction (LVEF) < 50 % and/or SVI assessed by echocardiography < 35 ml/m2; Thorough oral and written informed consent to participate in the study.
Exclusion: Other significant valvular diseases; Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (< 4 weeks); Contraindications to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT); End stage renal disease (eGFR of less than 15 mL/min/1,73 m2); Moderate to severe aortic stenosis (participants with aortic sclerosis will not be excluded).